Total Voting Rights

FOR IMMEDIATE RELEASE

16 September 2013

Source BioScience PLC ("Source BioScience" or the "company")

total voting rights

In accordance with the FCA's Disclosure and Transparency Rules, Source BioScience confirms that as at 13 September 2013 following completion of the Firm Placing and admission of the Firm Placing Shares, the Company has 312,873,965 ordinary shares of 2 pence each in issue.

The figure of 312,873,965 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, Source BioScience plc under the Disclosure and Transparency Rules. The voting rights of all ordinary shares in the Company rank pari passu and the Company does not hold any ordinary shares in treasury.

Enquiries

Source BioScience plc

Dr Nick Ash, CEO

Tel: +44 (0) 115 973 9010

Email: [email protected]

www.sourcebioscience.com

For investor and media enquiries:

N+1 Singer (Financial Advisor, Sponsor and Broker to Source BioScience)

Aubrey Powell/ Joseph Stroud/ Laura White

Tel: +44 (0)20 7496 3000

www.n1singer.com

College Hill (PR Agency to Source BioScience)

Melanie Toyne-Sewell/ Claire Dickinson

Tel: +44 (0)20 7457 2020

Email: [email protected]

About Source BioScience

Source BioScience plc (LSE: SBS) is an international diagnostics and genetic analysis business serving the healthcare and research markets. The LifeSciences division provides core laboratory research support from conceptualisation to implementation, calling upon a wide range of innovative technology platforms including an online catalogue of biomolecular tools. Source BioScience is a trusted provider of a complete range of sophisticated microarray, next generation and conventional sequencing services. GLP, GCP and CPA accreditations make the sequencing offerings very attractive for applications in regulatory studies or clinical settings. The Healthcare operations provide screening and reference laboratory diagnostic testing for cancer and other diseases in addition to complementary products for serology and diagnostic applications. Source BioScience has its headquarters in Nottingham, UK. For more information, see www.sourcebioscience.com.